JP Patent

JP2010505873A — 脂質含有製剤

Assigned to Alnylam Pharmaceuticals Inc · Expires 2010-02-25 · 16y expired

What this patent protects

核酸ベースの治療法、例えば、リポソーム及びリポプレックス等の会合複合体を投与するのに有用な組成物及び方法が説明される。

USPTO Abstract

核酸ベースの治療法、例えば、リポソーム及びリポプレックス等の会合複合体を投与するのに有用な組成物及び方法が説明される。

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: JP2010505873A
Jurisdiction: JP
Classification: —
Expires: 2010-02-25
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.